Observational study / 2019
Habitual glucosamine use was associated with a lower risk of cardiovascular disease events and CVD death in UK adults.
In the UK Biobank, 466,039 participants free of cardiovascular disease at baseline reported on supplement use and were followed for a median of seven years. Over follow-up, 10,204 incident CVD events, 3,060 CVD deaths, 5,745 coronary heart disease events, and 3,263 stroke events occurred. After multivariable adjustment, habitual glucosamine use was associated with a lower risk of total CVD events (HR 0.85, 95% CI 0.80 to 0.90), CVD death (HR 0.78, 95% CI 0.70 to 0.87), coronary heart disease (HR 0.82, 95% CI 0.76 to 0.88), and stroke (HR 0.91, 95% CI 0.83 to 1.00).
Shows an association, not proof of cause and effect.
- Study type
- Prospective cohort study
- Who was studied
- 466,039 UK Biobank participants without CVD at baseline
- What was measured
- Incident CVD events, including CVD death, coronary heart disease, and stroke
THE PAPER
Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank.
Ma H, Li X, Sun D, Zhou T, Ley SH, Gustat J, Heianza Y, Qi L. BMJ, 2019.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.